Subscribe To
Electrocore expands intellectual property portfolio for non-invasive vagus nerve stimulation (nvns) technology
ROCKAWAY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, t...
October 11, 2023, 12:00 pm
Patient with candida krusei infection in matinas biopharma’s oral mat2203 expanded access program achieves complete clinical resolution
BEDMINSTER, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on de...
October 11, 2023, 11:30 am
Silk road medical stock plummets on ceo exit and revenue downgrade
Silk Road Medical (NASDAQ:SILK) stock halved in value at the start of Wednesday's trading after an after-hours profit warning. The company, which has ...
October 11, 2023, 10:58 am
Tiziana life sciences to present ms treatment at ectrims annual congress
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that a late breaking poster titled, "Treatment Of...
October 11, 2023, 9:26 am
Vivos therapeutics to kick off clinical trial at stanford medicine
Vivos Therapeutics (NASDAQ:VVOS) Inc has announced that its flagship daytime-nighttime appliance (DNA) will be tested in a clinical trial at Stanford ...
October 11, 2023, 8:29 am
Labcorp launches 3-part blood test for alzheimer's
Labcorp on Wednesday began marketing to U.S. physicians the first test for a trio of blood biomarkers it says can detect the hallmarks of Alzheimer's,...
October 11, 2023, 7:34 am
Altimmune: a year of disappointment
Altimmune's stock has disappointed shareholders over the past year, with disappointing trial results triggering a significant drop in equity in March ...
October 11, 2023, 3:46 am
An2 therapeutics to present new data for epetraborole at idweek 2023
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing tre...
October 11, 2023, 12:01 am
Medicinova receives a notice of allowance for a new patent covering the combination of mn-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (als) in canada
LA JOLLA, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) an...
October 10, 2023, 11:00 pm
Sellas receives fda orphan drug designation for sls009 for treatment of acute myeloid leukemia
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clini...
October 10, 2023, 8:15 pm
Why shares of 89bio plummeted on tuesday
89bio is a clinical-stage biotech company. It focuses on treatments for liver and cardiometabolic disea...
October 10, 2023, 4:13 pm
Inovio shares rise after positive fda feedback on rrp treatment candidate
Biotechnology company Inovio saw its shares jump after the US FDA communicated that data from Inovio completed Phase 1/2 trial of INO-3107 for treatin...
October 10, 2023, 2:47 pm
Rayzebio: initiating coverage with buy rating and a price target of $43
Initiating RayzeBio, Inc. coverage with a Buy rating and common stock price target of $43 based on my risk-adjusted NPV discounted cash flow model, re...
October 10, 2023, 2:10 pm
Roche's (rhhby) vabysmo positive in late-stage rvo studies
Roche (RHHBY) Vabysmo maintains vision improvements with extended treatment intervals of up to four mon...
October 10, 2023, 1:32 pm
Cancer biotechs pique buyout interest: recent deals in focus
The M&A trend of 2023 shows that there is an increasing interest in biotech companies making innovative cancer tre...
October 10, 2023, 12:47 pm
Akero therapeutics inc stock tanks after nash liver treatment study disappoints
Akero Therapeutics Inc shares lost roughly two-thirds of their value Tuesday morning after the company released a disappointing update on its fatty li...
October 10, 2023, 11:51 am
Biotech stock sinks after disappointing trial
Akero Therapeutics Inc (NASDAQ:AKRO) is plummeting to 52-week lows, after its treatment for severe fatt...
October 10, 2023, 11:18 am
Annexon announces clinical and regulatory progress for anx005 pivotal program in guillain-barré syndrome (gbs)
ANX005 Granted Orphan Drug Designation by the European Medicines Agency for the Treatment of GBS Target...
October 10, 2023, 10:30 am
Merck immunotherapy shows further promise in lung cancer
Merck & Co confirmed that its cancer drug Keytruda has successfully met the second of its two primary targets in a phase III clinical trial, showi...
October 10, 2023, 9:11 am
Filament health says health canada authorizes phase 2 clinical trial studying botanical psilocybin for opioid use disorder
Filament Health Corp (OTCQB:FLHLF, NEO:FH) told investors that Health Canada has approved a phase 2 clinical trial of its botanical psilocybin drug ca...
October 10, 2023, 8:21 am